|Mr. Guido Baechler||CEO & Director||N/A||N/A||1965|
|Mr. William J. Caragol||Chief Financial Officer||N/A||N/A||1967|
|Mr. Philipp Freese||Chief Operating Officer||N/A||N/A||1983|
|Dr. Moritz Eidens Ph.D.||Chief Science Officer & Director||N/A||N/A||1984|
|Stefan Erlach||Head of HR||N/A||N/A||N/A|
|Mr. Darin S. Leigh||Chief Commercial Officer||N/A||N/A||N/A|
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Mainz Biomed B.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.